What is PHAR stock price today?

PHAR (Pharming Group Nv) stock is trading at $17.80 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is PHAR stock going up or down today?

PHAR stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy PHAR stock now?

The decision to buy PHAR depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is PHAR a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for PHAR based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is PHAR stock overvalued or undervalued?

PHAR currently trades at a P/E ratio of 442.00, which may indicate premium valuation. Our DCF calculator provides intrinsic value estimates to help determine if PHAR is fairly priced.

What is PHAR's P/E ratio?

PHAR has a price-to-earnings (P/E) ratio of 442.00, which measures how much investors are willing to pay per dollar of earnings. Compare this to industry peers and historical averages for context.

What is PHAR's market cap?

PHAR (Pharming Group Nv) has a market capitalization of $1.25 billion, making it a small-cap stock.

What is PHAR's price to book ratio?

PHAR trades at a price-to-book (P/B) ratio of 4.51, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does PHAR pay dividends?

PHAR does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is PHAR's dividend yield?

PHAR does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is PHAR stock a good long-term investment?

PHAR's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is PHAR's revenue growth rate?

PHAR has shown revenue growth of 0.1% over recent periods. Consistent revenue growth is a key indicator of business health and competitive positioning.

Yes, PHAR is profitable with a profit margin of 0.0%. This indicates the company generates 0.0 cents of profit for every dollar of revenue.

What are the risks of investing in PHAR?

Key risks for PHAR include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does PHAR compare to its competitors?

Compare PHAR to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize PHAR's performance and positioning.

What is PHAR's stock price target for 2026?

Our AI model provides price targets for PHAR based on fundamental analysis: Bull case $23.14 (+30%), Base case $20.47 (+15%), Bear case $16.02 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about PHAR?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for PHAR. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is PHAR's next earnings report?

PHAR reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

PHAR - Pharming Group Nv

NYSE * Health Care * Biotechnology

$17.80

+$0.12 (+0.68%)

About Pharming Group Nv

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops Joenja, an oral small molecule PI3K" inhibitor. It has a development collaboration and license agreement with Novartis. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

PHAR Key Statistics

Market Cap

$1.25B

P/E Ratio

442.00

P/B Ratio

4.51

EPS

$0.04

Revenue Growth

+0.1%

Profit Margin

0.0%

Employees

407

How PHAR Compares to Peers

PHAR trades at a premium valuation vs peers (highest P/E)

PHAR has the fastest revenue growth among competitors

PHAR is the smallest among peers, which may offer higher growth potential

P/E Rank

of 6

Margin Rank

of 6

Growth Rank

of 6

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
PHAR(This stock)	$1.25B	442.0	0%	0.0%	-
AMGNAmgen Inc	$187.71B	24.5	0%	0.2%	vs AMGN
GILDGilead Sciences	$173.48B	20.6	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$112.35B	28.8	0%	0.3%	vs VRTX
REGNRegeneron Pharmaceuticals	$79.71B	18.2	0%	0.3%	vs REGN
BIIBBiogen Inc	$25.83B	20.0	-0%	0.1%	vs BIIB

Pharming Group Nv Company Information

Headquarters: Netherlands
Website: www.pharming.com
Sector: Health Care
Industry: Biotechnology

About Pharming Group Nv

PHAR Key Statistics

How PHAR Compares to Peers

Pharming Group Nv Company Information

Upcoming Events for PHAR